Payment overview · 2025
General Payments
$498.69
17 reported records · 9 companies
Healthcare provider profile · identity verified
Laila Farhat
Allopathic & Osteopathic Physicians|General Practice · BROOKLYN, NY · NPI 1083786362
Verified facts
What the public records show
CMS Open Payments records show Laila Farhat received $498.69 in general payments during 2025 across 17 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.68 | 25.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.87 | 24.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.39 | 13.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.14 | 9.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.31 | 8.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.83 | 5.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.17 | 4.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.10 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.20 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.69 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.68 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $65.39 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.14 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 304 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 176 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
178 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
304 | 51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
304 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
176 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
228 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1006 | 214 |
| Metformin Hcl | Metformin Hcl | 981 | 180 |
| Enalapril Maleate | Enalapril Maleate | 583 | 117 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 487 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 98 |
| Omeprazole | Omeprazole | 423 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 64 |
| Allopurinol | Allopurinol | 313 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 64 |
| Jardiance | Empagliflozin | 304 | 51 |
| Sertraline Hcl | Sertraline Hcl | 268 | 61 |
| Gabapentin | Gabapentin | 263 | 64 |
| Ozempic | Semaglutide | 228 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 42 |
| Famotidine | Famotidine | 224 | 38 |
| Januvia | Sitagliptin Phosphate | 205 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 202 | 54 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 180 | 37 |
| Linzess | Linaclotide | 178 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 64 |
| Mounjaro | Tirzepatide | 176 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 39 |
| Simvastatin | Simvastatin | 171 | 37 |
| Losartan Potassium | Losartan Potassium | 167 | 34 |
| Alendronate Sodium | Alendronate Sodium | 164 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 154 | 53 |
| Chlorthalidone | Chlorthalidone | 153 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 37 |
| Donepezil Hcl | Donepezil Hcl | 145 | 27 |
| Celecoxib | Celecoxib | 144 | 44 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 140 | 34 |
| Montelukast Sodium | Montelukast Sodium | 136 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 129 | 32 |
| Ezetimibe | Ezetimibe | 123 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 25 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 110 | 17 |
| Baclofen | Baclofen | 109 | 49 |
| Breo Ellipta | Fluticasone/Vilanterol | 102 | 19 |
| Trazodone Hcl | Trazodone Hcl | 100 | 19 |
| Farxiga | Dapagliflozin Propanediol | 95 | 16 |
| Lisinopril | Lisinopril | 89 | 18 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 87 | suppressed |
| Meloxicam | Meloxicam | 85 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 84 | 20 |
| Eliquis | Apixaban | 82 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 32 |
| Nifedipine Er | Nifedipine | 69 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 16 |
| Carvedilol | Carvedilol | 61 | 11 |
| Tramadol Hcl | Tramadol Hcl | 61 | 16 |
| Vascepa | Icosapent Ethyl | 61 | 11 |
| Ibuprofen | Ibuprofen | 60 | 36 |
| Furosemide | Furosemide | 57 | 16 |
| Prednisone | Prednisone | 57 | 38 |
| Fluocinonide-E | Fluocinonide/Emollient Base | 56 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 53 | 20 |
| Incruse Ellipta | Umeclidinium Bromide | 52 | 13 |
| Olanzapine | Olanzapine | 52 | 20 |
| Novolog Flexpen | Insulin Aspart | 50 | 13 |
| Xarelto | Rivaroxaban | 50 | 12 |
| Azithromycin | Azithromycin | 48 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Valsartan | Valsartan | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 39 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 34 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 27 |
| Spiriva Handihaler | Tiotropium Bromide | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 26 | suppressed |
| Tacrolimus | Tacrolimus | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Trulance | Plecanatide | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Prolia | Denosumab | 16 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Novofine Plus | Pen Needle, Diabetic | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.69 · 17 records | Boehringer Ingelheim Pharmaceuticals, Inc. | FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error